Daiichi Sankyo submits edoxaban to European regulators

|About: Daiichi Sankyo Co., Ltd. (DSKYF)|By:, SA News Editor

Daiichi Sankyo (DSKYF +1.2%) submits a MAA for edoxaban.

The company wants the direct factor Xa-inhibitor approved for stroke and SEE prevention in NVAF patients, for the treatment of DVT or PE, and for the prevention of VTE.

For more on edoxaban, see here.